CellSource Co., Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥5 | 0.0% |
| 2024 | ¥5 | -75.0% |
| 2023 | ¥20 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥4,274M | ¥4,511M | ¥4,355M | ¥3,711M |
| Gross Profit | ¥3,064M | ¥3,185M | ¥2,417M | ¥2,087M |
| Operating Income | ¥1,571M | ¥1,222M | ¥129M | ¥167M |
| Pretax Income | ¥1,584M | ¥1,240M | ¥296M | ¥111M |
| Net Income | ¥1,018M | ¥923M | ¥238M | ¥11M |
| EPS | ¥52.98 | ¥47.93 | ¥11.96 | ¥0.54 |
| Operating Margin | 36.76% | 27.08% | 2.97% | 4.49% |
| Balance Sheet | ||||
| Total Assets | ¥4,600M | ¥6,880M | ¥7,075M | ¥7,024M |
| Total Equity | ¥3,786M | ¥6,202M | ¥6,037M | ¥6,017M |
| Total Liabilities | ¥814M | ¥678M | ¥1,038M | ¥1,007M |
| Cash | ¥3,124M | ¥4,781M | ¥4,321M | ¥4,712M |
| Interest-bearing Debt | ¥0M | ¥98M | ¥77M | ¥57M |
| Equity Ratio | 82.30% | 90.15% | 85.33% | 85.66% |
| D/E Ratio | 0.00 | 0.02 | 0.01 | 0.01 |
| Cash Flow | ||||
| Operating CF | ¥848M | ¥847M | ¥592M | ¥333M |
| Investing CF | -¥169M | -¥624M | -¥615M | -¥3M |
| Financing CF | ¥14M | ¥1,449M | -¥437M | ¥61M |
| Free CF | ¥748M | ¥488M | ¥52M | ¥283M |
| Efficiency | ||||
| ROE | 26.89% | 14.88% | 3.94% | 0.18% |
| ROA | 22.13% | 13.42% | 3.36% | 0.15% |
Latest IR Information
-
For the Fiscal Year Ending October 2026, July Monthly KPI Flash
As a monthly KPI flash, discloses the daily average number of subcontracted processing cases on a month-over-month and year-over-year basis. The report presents trends in the number of cases for hybrid-type orthopedic devices, internal demand, and order volumes with charts...
Read more -
CellSource FY2026 Earnings Forecast and Transition to Non-Consolidated Financial Statements | July 29, 2026
CellSource will transition to non-consolidated accounting beginning from the third quarter of FY2026 (October 2025 quarter), recording a special profit of 65 million yen related to absorption merger. The forecast for FY2026 individual sales is 3,320 million yen, with a...
Read more -
Monthly KPI速報 for June 2026 Interim Period (October 2026 Term)
Read more -
Notice Regarding the Recording of Non-Operating Expenses
Read more -
Notice Regarding the Recording of Non-Operating Expenses
Read more
Latest News (5 items)
Company Information
About
CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients' adipose tissues, and to prepare platelet-rich plasma from patients' blood; and offers support services for medical facilities providing regenerative medicine therapy. It is also involved in the sale of human stem cell-derived cosmetic ingredients; and Signalift series of anti-aging products, including a serum. The company was incorporated in 2015 and is headquartered in Shibuya, Japan.
